The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once-daily oral administration of BLI5100 versus a Proton-pump inhibitors control in healing Erosive Esophagitis. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once-daily oral administration of BLI5100 (low or high dose) versus a Proton-pump inhibitors control in the maintenance of healed Erosive Esophagitis.
Criteria:Aged ≥18 years at the time of signing an informed consent
Have experienced both heartburn and regurgitation within 7 days prior to the Screening Visit
Current evidence of EE of LA grades A to D based on an upper GI endoscopy
Able to understand and comply with the protocol requirements
Willing and able to provide written informed consent at Screening